Clinical Trial Update: A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Relugolix (TAK-385) 40 mg with Leuprorelin in treating uterine fibroids has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• Relugolix (TAK-385) (relugolix)

Snippet

Sponsor: Takeda | Conditions: Uterine Fibroids | Phase 3 | Status: COMPLETED | Results posted: 2019-03-22